Get started
Author

Marine Perrier

Endoscopic Ultrasound-guided Radiofrequency Ablation Versus Surgical Resection for Treatment of Pancreatic Insulinoma
2023 · Stefano Francesco Crinò, Bertrand Napoleon, et al. · Clinical Gastroenterology and Hepatology · 119
PDF
Hemicolectomy versus appendectomy for patients with appendiceal neuroendocrine tumours 1–2 cm in size: a retrospective, Europe-wide, pooled cohort study
2023 · Cédric Nesti, Konstantin Bräutigam, et al. · The Lancet Oncology · 68
PDF
Correlation between muscle mass and handgrip strength in digestive cancer patients undergoing chemotherapy
2019 · Johanna Moreau, Marie‐Amélie Ordan, et al. · Cancer Medicine · 54
PDF
Bevacizumab plus FOLFIRI after failure of platinum–etoposide first-line chemotherapy in patients with advanced neuroendocrine carcinoma (PRODIGE 41-BEVANEC): a randomised, multicentre, non-comparative, open-label, phase 2 trial
2023 · Thomas Walter, Astrid Lievre, et al. · The Lancet Oncology · 53
Dynapenia could predict chemotherapy-induced dose-limiting neurotoxicity in digestive cancer patients
2018 · Damien Botsen, Marie-Amélie Ordan, et al. · BMC Cancer · 37
PDF
Surgery and Perioperative Management in Small Intestinal Neuroendocrine Tumors
2020 · Sophie Deguelte, Marine Perrier, et al. · Journal of Clinical Medicine · 36
PDF
Treatment outcomes of advanced digestive well-differentiated grade 3 NETs
2021 · Louis de Mestier, Angela Lamarca, et al. · Endocrine Related Cancer · 32
PDF
Feasibility of systematic handgrip strength testing in digestive cancer patients treated with chemotherapy: The FIGHTDIGO study
2017 · Marie‐Amélie Ordan, Camille Mazza, et al. · Cancer · 26
PDF
Oxaliplatin-Based Versus Alkylating Agent in Neuroendocrine Tumors According to the O 6 -Methylguanine-DNA Methyltransferase Status: A Randomized Phase II Study (MGMT-NET)
2024 · Thomas Walter, Thierry Lecomte, et al. · Journal of Clinical Oncology · 22
Renal impairment and abnormal liver function tests in pre-therapeutic phenotype-based DPD deficiency screening using uracilemia: a comprehensive population-based study in 1138 patients
2023 · Sidonie Callon, Mathias Brugel, et al. · Therapeutic Advances in Medical Oncology · 18
PDF
FOLFOX ‐bevacizumab chemotherapy in patients with metastatic neuroendocrine tumors
2022 · Caroline Lacombe, Marine Perrier, et al. · Journal of Neuroendocrinology · 16
PDF
Second-line treatment and prognostic factors in neuroendocrine carcinoma: the RBNEC study
2022 · Julien Hadoux, Thomas Walter, et al. · Endocrine Related Cancer · 15
Peptide Receptor Radionuclide Therapy or Everolimus in Metastatic Neuroendocrine Tumors: The SeqEveRIV Study, a National Study from the French Group of Endocrine Tumors and Endocan–RENATEN Network
2024 · Aurelien Fosse, Julien Hadoux, et al. · Journal of Nuclear Medicine · 13
PDF
Characteristics and treatment options of glucagonomas: a national study from the French Group of Endocrine Tumors and ENDOCAN-RENATEN network
2023 · Marine Perrier, Mathias Brugel, et al. · European Journal of Endocrinology · 11
Association of Low Handgrip Strength with Chemotherapy Toxicity in Digestive Cancer Patients: A Comprehensive Observational Cohort Study (FIGHTDIGOTOX)
2022 · Pierre Martin, Damien Botsen, et al. · Nutrients · 11
PDF
FOLFIRI plus BEvacizumab or aFLIbercept after FOLFOX ‐bevacizumab failure for COlorectal cancer ( BEFLICO ): An AGEO multicenter study
2022 · Cécile Torregrosa, Simon Pernot, et al. · International Journal of Cancer · 11
Dynapenia in digestive cancer outpatients: association with markers of functional and nutritional status (the FIGHTDIGO study)
2021 · Marine Perrier, Marie-Amelie Ordan, et al. · Supportive Care in Cancer · 11
Beta-blocker exposure and survival outcomes in patients with advanced pancreatic ductal adenocarcinoma: a retrospective cohort study (BETAPANC)
2023 · Antoine Le Bozec, Mathias Brugel, et al. · Frontiers in Pharmacology · 10
PDF
Impact of Cold Somatostatin Analog Administration on Somatostatin Receptor Imaging
2023 · David Morland, Nicolas Laures, et al. · Clinical Nuclear Medicine · 10
Alkylating agent rechallenge in metastatic pancreatic neuroendocrine tumors
2021 · Ophélie De Rycke, Thomas Walter, et al. · Endocrine Related Cancer · 9
Impact of low muscle mass and myosteatosis on treatment toxicity and survival outcomes in non-resectable pancreatic cancer patients treated with chemoradiotherapy
2025 · Marine Perrier, Marine Fontaine, et al. · European Journal of Clinical Nutrition · 8
PDF
Association between pancreatic adenocarcinoma risk and concentration of organochlorine pesticides in adipose tissue and urine: A targeted‐screening analysis case‐control study (PESTIPAC)
2024 · Mathias Brugel, Sidonie Callon, et al. · United European Gastroenterology Journal · 8
PDF
High Tumor Uptake on 18 F-FDOPA PET/CT Indicates Poor Prognosis in Patients with Metastatic Midgut Neuroendocrine Tumors: A Study from the Groupe dtude des Tumeurs Endocrines and ENDOCAN-RENATEN Network
2023 · Ophlie De Rycke, Marine Perrier, et al. · Journal of Nuclear Medicine · 8
PDF
Cannabidiol–drug interaction in cancer patients: A retrospective study in a real‐life setting
2023 · Marie Guedon, Antoine Le Bozec, et al. · British Journal of Clinical Pharmacology · 8
PDF
Total gastrectomy for severe proton pump inhibitor-induced hypomagnesemia in a MEN1/Zollinger Ellison syndrome patient
2020 · Marine Perrier, Brigitte Delemer, et al. · Pancreatology · 8
PDF
Works count: 70
Citation count: 699
H-index: 12
I10-index: 19
Year
Topic
Type